These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 22433756

  • 1. Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial.
    Shiroiwa T, Takeuchi T, Fukuda T, Shimozuma K, Ohashi Y.
    Value Health; 2012; 15(2):255-60. PubMed ID: 22433756
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S, Chancellor JV, Raikou M, Drummond MF, Weinstein MC, Jourdan S, Bridgewater J.
    Cancer; 2007 Mar 15; 109(6):1082-9. PubMed ID: 17265519
    [Abstract] [Full Text] [Related]

  • 3. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
    Hsu TC, Chen HH, Yang MC, Wang HM, Chuang JH, Jao SW, Chiang HC, Wen CY, Tseng JH, Chen LT.
    Value Health; 2011 Mar 15; 14(5):647-51. PubMed ID: 21839401
    [Abstract] [Full Text] [Related]

  • 4. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
    Mullins CD, Hsiao FY, Onukwugha E, Pandya NB, Hanna N.
    Cancer; 2012 Jun 15; 118(12):3173-81. PubMed ID: 22020739
    [Abstract] [Full Text] [Related]

  • 5. Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand.
    Lerdkiattikorn P, Chaikledkaew U, Lausoontornsiri W, Chindavijak S, Khuhaprema T, Tantai N, Teerawattananon Y.
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun 15; 15(4):687-700. PubMed ID: 25327502
    [Abstract] [Full Text] [Related]

  • 6. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
    Cassidy J, Douillard JY, Twelves C, McKendrick JJ, Scheithauer W, Bustová I, Johnston PG, Lesniewski-Kmak K, Jelic S, Fountzilas G, Coxon F, Díaz-Rubio E, Maughan TS, Malzyner A, Bertetto O, Beham A, Figer A, Dufour P, Patel KK, Cowell W, Garrison LP.
    Br J Cancer; 2006 Apr 24; 94(8):1122-9. PubMed ID: 16622438
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.
    Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K.
    Pharmacoeconomics; 2009 Apr 24; 27(7):597-608. PubMed ID: 19663530
    [Abstract] [Full Text] [Related]

  • 8. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
    Pandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P.
    Health Technol Assess; 2006 Nov 24; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
    [Abstract] [Full Text] [Related]

  • 9. Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer.
    Goldstein DA, Chen Q, Ayer T, Howard DH, Lipscomb J, Harvey RD, El-Rayes BF, Flowers CR.
    Clin Colorectal Cancer; 2014 Dec 24; 13(4):219-25. PubMed ID: 25306485
    [Abstract] [Full Text] [Related]

  • 10. CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis.
    Alarid-Escudero F, Schrag D, Kuntz KM.
    Value Health; 2022 Mar 24; 25(3):409-418. PubMed ID: 35227453
    [Abstract] [Full Text] [Related]

  • 11. Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.
    Di Costanzo F, Ravasio R, Sobrero A, Bertetto O, Vinante O, Luppi G, Labianca R, Amadori D, Barone C, Carlo Merlano M, Longo F, Mansueto G, Antonuzzo L, Gasperoni S.
    Clin Drug Investig; 2008 Mar 24; 28(10):645-55. PubMed ID: 18783303
    [Abstract] [Full Text] [Related]

  • 12. Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study.
    Koperna T, Semmler D.
    Hepatogastroenterology; 2003 Mar 24; 50(54):1903-9. PubMed ID: 14696430
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
    Hillner BE, Schrag D, Sargent DJ, Fuchs CS, Goldberg RM.
    Cancer; 2005 Nov 01; 104(9):1871-84. PubMed ID: 16177989
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.
    Wen F, Yao K, Du ZD, He XF, Zhang PF, Tang RL, Li Q.
    World J Gastroenterol; 2014 Dec 21; 20(47):17976-84. PubMed ID: 25548497
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancer.
    Ayvaci MU, Shi J, Alagoz O, Lubner SJ.
    Med Decis Making; 2013 May 21; 33(4):521-32. PubMed ID: 23313932
    [Abstract] [Full Text] [Related]

  • 16. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont A.
    J Clin Oncol; 2015 Dec 10; 33(35):4176-87. PubMed ID: 26527776
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T, Fukuda T, Tsutani K.
    Clin Ther; 2007 Oct 10; 29(10):2256-67. PubMed ID: 18042483
    [Abstract] [Full Text] [Related]

  • 18. Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers.
    Soni A, Aspinall SL, Zhao X, Good CB, Cunningham FE, Chatta G, Passero V, Smith KJ.
    Oncol Res; 2014 Oct 10; 22(5-6):311-9. PubMed ID: 26629943
    [Abstract] [Full Text] [Related]

  • 19. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
    Kim JY, Kim YJ, Lee KW, Lee JS, Kim DW, Kang SB, Lee HS, Jang NY, Kim JS, Kim JH.
    Jpn J Clin Oncol; 2013 Feb 10; 43(2):132-8. PubMed ID: 23204187
    [Abstract] [Full Text] [Related]

  • 20. An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK).
    Aballéa S, Boler A, Craig A, Wasan H.
    Eur J Cancer; 2007 Jul 10; 43(11):1687-93. PubMed ID: 17587564
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.